Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Authors' reply

    Research output: Contribution to journalComment/debateResearch

  3. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Endometrial cancer risk after fertility treatment: a population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Christian Dehlendorff
  • Pär Sparén
  • Birgitte Baldur-Felskov
  • Eva Herweijer
  • Lisen Arnheim-Dahlström
  • Alexander Ploner
  • Ingrid Uhnoo
  • Susanne K Kjaer
View graph of relations

BACKGROUND: Based on immunogenicity studies, a 2 dose HPV vaccination-schedule was recently recommended for girls younger than 15 years. We aimed to investigate the effectiveness of quadrivalent HPV (qHPV) vaccination against CIN2 or worse (CIN2+), by age at vaccination, number of doses, and to test whether optimal timing of 2 doses of qHPV vaccine can confer the same level of protection as the originally recommended three dose-schedule.

METHODS: A population-based cohort of all women aged 13-30 years, living in Denmark or Sweden during 2006-2013, was followed for qHPV vaccination status and first occurrence of CIN2+.

RESULTS: The study cohort comprised 2,253,561 women, of which 33% were vaccinated during follow-up, and 1.7% were diagnosed with CIN2+. Vaccination at ages 13-16 and 17-19 was associated with a reduced risk of CIN2+ after 3 doses (IRR = 0.23, 95% CI 0.11-0.49, and IRR = 0.65, 95% CI 0.41-1.03, respectively), compared to being unvaccinated. After 1 and 2 doses there was a reduced risk, but not statistically significant. Women vaccinated ages 13-16 with 2 doses, where time between first and second dose was 5 months or longer showed no difference in risk compared to 3 doses.

CONCLUSIONS: Women vaccinated with 3 doses of qHPV showed a reduced risk of CIN2+ if they were vaccinated before age 20, with a further reduced risk if vaccinated before age 17. Vaccination with 2 doses, with the second dose 5 months or longer after the first dose, did not yield an increased risk of CIN2+, compared to 3 doses.

Original languageEnglish
JournalVaccine
Volume36
Issue number43
Pages (from-to)6373-6378
Number of pages6
ISSN0264-410X
DOIs
Publication statusPublished - 15 Oct 2018

ID: 56088884